

IN THE CLAIMS:

RECEIVED
CENTRAL FAX CENTER
JUN 23 2008

Claims 1-130 (canceled).

131. (new) A pharmaceutical composition for inducing or accelerating a healing process of a skin wound, the pharmaceutical composition comprising insulin, a PKC α inhibitor consisting of the myristoylated peptide of SEQ ID NO: 1, and a pharmaceutically acceptable carrier.

132. (new) A pharmaceutical composition for inducing or accelerating a healing process of a skin wound, the pharmaceutical composition comprising a therapeutically effective amount of insulin and a PKC α , and pharmaceutically acceptable carrier, wherein the pharmaceutical composition is for a topical application.

133. (new) A pharmaceutical composition a single dose-unit of insulin and a pharmaceutically acceptable carrier, wherein the single dose-unit comprises a sufficient amount of said insulin to induce or accelerate a healing process of the skin wound in a subject..

134. (new) The pharmaceutical composition of claim 133, wherein said pharmaceutical composition is for topical administration.

135. (new) The pharmaceutical composition of claim 133, wherein said insulin is recombinant.

136. (new) The pharmaceutical composition of claim 133, wherein said insulin is from a natural source.

137. (new) The pharmaceutical composition of claim 133, wherein the formulation is an aqueous solution, a gel, a cream, a paste, a lotion, a spray, a suspension, a powder, a dispersion, a salve or an ointment.

138. (new) An article of manufacture comprising the pharmaceutical composition of claim 137 applied on a solid support.

139. (new) A composition comprising insulin, a buffer and a PKC α inhibitor consisting of SEQ ID NO: 1.

140. (new) A composition comprising the myristoylated peptide of SEQ ID NO: 1 and a pharmaceutically acceptable buffer.

141. (new) A pharmaceutical composition comprising the myristoylated peptide of SEQ ID NO: 1.

142. (new) The pharmaceutical composition of claim 141, further comprising insulin.

143. (new) A composition comprising recombinant human insulin, the myristoylated peptide of SEQ ID NO: 1 and a pharmaceutically acceptable buffer.

144. (new) A pharmaceutical composition comprising a therapeutically effective amount of insulin, a buffer and a PKC α inhibitor, wherein said composition promotes wound healing when applied to a patient in need thereof..